Ab­b­Vie, Gen­mab land FDA OK for CD3xCD20 bis­pe­cif­ic, catch­ing up with Roche

Ab­b­Vie and Gen­mab have land­ed an ac­cel­er­at­ed FDA ap­proval for their CD3xCD20 bis­pe­cif­ic, adding an op­tion for pa­tients with re­lapsed/re­frac­to­ry large B cell lym­phoma.

While the com­pa­nies are com­ing in sec­ond af­ter Roche’s Genen­tech — whose bis­pe­cif­ic mo­sune­tuzum­ab was ap­proved as Lun­sumio in De­cem­ber — they note that their drug, ep­cori­ta­m­ab, is the first sub­cu­ta­neous bis­pe­cif­ic an­ti­body ap­proved as a third-line treat­ment of this can­cer type. It will be mar­ket­ed as Ep­kin­ly. The treat­ment has a month­ly list price of $37,500, ac­cord­ing to a spokesper­son, who not­ed that the av­er­age du­ra­tion of ther­a­py is about nine months.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN